Login to Your Account


Lumena Pharmaceuticals lights up biotech IPO runway with $75M filing

By Marie Powers
Staff Writer

Thursday, April 3, 2014
Undeterred by the Street’s recent biotech selloff, Lumena Pharmaceuticals Inc. took its place on the initial public offering (IPO) runway, seeking to raise $75 million to advance two drugs designed to treat rare cholestatic liver diseases and serious metabolic disorders, including nonalcoholic steatohepatitis (NASH).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription